Loading...
•
Mar 31, 2023
Enliven Therapeutics Q1 2023 Earnings Report
Reported financial results for the first quarter ended March 31, 2023 and provided a business update.
Key Takeaways
Enliven Therapeutics reported a net loss of $14.7 million for the first quarter of 2023. The company's cash and cash equivalents totaled $292.1 million as of March 31, 2023, expected to fund operations into early 2026.
Successfully completed merger with Imara Inc., trading under the new ticker symbol on Nasdaq, “ELVN”.
Dosed first patient in Phase 1 study of ELVN-002 in patients with HER2-altered non-small cell lung cancer (NSCLC) and other solid tumors.
Enrollment progressing in Phase 1 trial with ELVN-001 in chronic myeloid leukemia (CML).
Ended the first quarter 2023 with cash and cash equivalents of approximately $292 million, which is expected to provide cash runway into early 2026.
Forward Guidance
The company expects to share initial safety and efficacy data from the Phase 1a study in 2024 for both ELVN-001 and ELVN-002 programs.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...